VolitionRX (VNRX) Stock: Buy, Sell, or Hold?
VNRX - VolitionRX Limited Common Stock
$0.23
-0.02 (-9.03%)
▼
5d:
-4.52%
30d:
-40.46%
90d:
-83.24%
WAIT
LOW Confidence
Analysis Updated: Sep 30, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When VNRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: VNRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: VNRX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: VNRX is currently trading at $0.23, which is considered oversold relative to its 30-day fair value range of $0.25 to $0.39. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.3) compared to its historical average (0.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VNRX is in a strong downtrend. The price is currently testing key support at $0.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.0% recently.
Market Sentiment: VNRX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $13.62 (+5179.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VNRX is in a strong downtrend. The price is currently testing key support at $0.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.0% recently.
Market Sentiment: VNRX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $13.62 (+5179.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.25 -
$0.39
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.0%)
- BULLISH: Trading 5179.8% below Wall St target ($13.62)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.25 -
$0.39
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.23
Resistance Level
$0.28
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.30
Wall Street Target
$13.62
(+5179.8%)
Revenue Growth (YoY)
-2.0%
PE vs Historical
-0.3 vs 0.6
CHEAP
Share & Embed Analysis
Last updated: October 01, 2026 4:10 PM ET
Data refreshes hourly during market hours. Next update: 5:10 PM
Data refreshes hourly during market hours. Next update: 5:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VNRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 57 HOLD |
